Roopa Lakhanpal1, Ivana Sestak2, Bruce Shadbolt3, Genevieve M Bennett4, Michael Brown4, Tessa Phillips4, Yanping Zhang5, Amanda Bullman6, Angela Rezo7. 1. FRANZCR, Department of Radiation Oncology, The Canberra Hospital, Canberra, Australia. Electronic address: rupalakhanpal@gmail.com. 2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, London, UK. 3. Centre for Advances in Epidemiology and IT, The Canberra Hospital, Canberra, Australia. 4. RCPA, Department of ACT Pathology, The Canberra Hospital, Canberra, Australia. 5. ACT and SE NSW Breast Cancer Treatment Group, ACT Health, GPO Box 825, ACT 2601, Australia. 6. Department of ACT Pathology, The Canberra Hospital, Canberra, Australia. 7. FRANZCR, Department of Radiation Oncology, The Canberra Hospital, Canberra, Australia.
Abstract
PURPOSE: Immunohistochemical 4 (IHC4) score plus Clinical Treatment Score (CTS) is an inexpensive tool predicting risk of distant recurrence in women with early breast cancer (EBC). IHC4 score is based on ER, PR, HER2 and Ki67 index. This study explores the role of the combined score (IHC4 + CTS) in predicting risk of locoregional recurrence (LRR) in women with EBC who had breast conservation surgery (BCS) without adjuvant radiotherapy (study group). The secondary objective was to evaluate the clinicopathological differences between our study group and women who had adjuvant radiation following BCS (control group). METHODS AND MATERIALS: Patients were selected from the local database over a 13-year period. IHC testing was done where results were missing. Combined scores were calculated using the appropriate formulae. RESULTS: Patients in the study group (81 patients) had favorable clinicopathological features compared to the control group (1406 patients). The Cox regression indicated a statistically significant association between the combined score and the risk of LRR (p = 0.03). The incidence of LRR was zero, 20% and 33.3% in the low, intermediate and high risk groups respectively (p = 0.007). Margin status was the only variable not included in the combined score. The Cox regression analysis demonstrated that the combined score (p = 0.02) and the ordinal measure of margins (p = 0.03) were significant independent predictors of LRR. CONCLUSION: This is the first study of its kind. The IHC4 score + CTS can be used to identify low risk women who can potentially avoid adjuvant radiotherapy.
PURPOSE: Immunohistochemical 4 (IHC4) score plus Clinical Treatment Score (CTS) is an inexpensive tool predicting risk of distant recurrence in women with early breast cancer (EBC). IHC4 score is based on ER, PR, HER2 and Ki67 index. This study explores the role of the combined score (IHC4 + CTS) in predicting risk of locoregional recurrence (LRR) in women with EBC who had breast conservation surgery (BCS) without adjuvant radiotherapy (study group). The secondary objective was to evaluate the clinicopathological differences between our study group and women who had adjuvant radiation following BCS (control group). METHODS AND MATERIALS: Patients were selected from the local database over a 13-year period. IHC testing was done where results were missing. Combined scores were calculated using the appropriate formulae. RESULTS:Patients in the study group (81 patients) had favorable clinicopathological features compared to the control group (1406 patients). The Cox regression indicated a statistically significant association between the combined score and the risk of LRR (p = 0.03). The incidence of LRR was zero, 20% and 33.3% in the low, intermediate and high risk groups respectively (p = 0.007). Margin status was the only variable not included in the combined score. The Cox regression analysis demonstrated that the combined score (p = 0.02) and the ordinal measure of margins (p = 0.03) were significant independent predictors of LRR. CONCLUSION: This is the first study of its kind. The IHC4 score + CTS can be used to identify low risk women who can potentially avoid adjuvant radiotherapy.
Authors: Mark Francis Evans; Pamela Mary Vacek; Brian Lee Sprague; Gary Stephen Stein; Janet Lee Stein; Donald Lee Weaver Journal: J Cell Biochem Date: 2019-10-08 Impact factor: 4.429
Authors: M C De Santis; E La Rocca; E Meneghini; G Bregni; G Di Lorenzo; G Galli; M Di Nicola; S Folli; M Gennaro; G Pruneri; B Paolini; M G Daidone; F De Braud; G Apolone; M Sant; S Di Cosimo Journal: Clin Transl Oncol Date: 2019-08-01 Impact factor: 3.405
Authors: Bradley M Turner; Mary Ann Gimenez-Sanders; Armen Soukiazian; Andrea C Breaux; Kristin Skinner; Michelle Shayne; Nyrie Soukiazian; Marilyn Ling; David G Hicks Journal: Cancer Med Date: 2019-06-14 Impact factor: 4.452
Authors: Mustapha Abubakar; Jonine Figueroa; H Raza Ali; Fiona Blows; Jolanta Lissowska; Carlos Caldas; Douglas F Easton; Mark E Sherman; Montserrat Garcia-Closas; Mitch Dowsett; Paul D Pharoah Journal: Mod Pathol Date: 2019-04-11 Impact factor: 7.842
Authors: Jared L Katzman; Uri Shaham; Alexander Cloninger; Jonathan Bates; Tingting Jiang; Yuval Kluger Journal: BMC Med Res Methodol Date: 2018-02-26 Impact factor: 4.615